J N Sama1, N Chida2, R M Polan3, J Nuzzo4, K Page5, M Shah6. 1. The Johns Hopkins University School of Medicine, 733 North Broadway, Baltimore, MD 21205, USA. Electronic address: jsama1@jhu.edu. 2. The Johns Hopkins University School of Medicine, 733 North Broadway, Baltimore, MD 21205, USA. Electronic address: Nchida1@jhmi.edu. 3. The Johns Hopkins University School of Medicine, 733 North Broadway, Baltimore, MD 21205, USA. Electronic address: rpolan1@jhmi.edu. 4. Johns Hopkins University School of Public Health, 615 North Wolfe Street, Baltimore, MD 21205, USA; UPMC Center for Health Security, 621 East Pratt Street, Baltimore, MD 21202, USA. Electronic address: jnuzzo1@jhu.edu. 5. The Johns Hopkins University School of Medicine, 733 North Broadway, Baltimore, MD 21205, USA; Baltimore City Health Department, 620 North Caroline Street, Baltimore, MD 21205, USA. Electronic address: kpage2@jhmi.edu. 6. The Johns Hopkins University School of Medicine, 733 North Broadway, Baltimore, MD 21205, USA; Baltimore City Health Department, 620 North Caroline Street, Baltimore, MD 21205, USA. Electronic address: mshah28@jhmi.edu.
Abstract
OBJECTIVES: The proportion of extrapulmonary tuberculosis (EPTB) cases in the United States (US) has been rising due to a slower rate of decline in EPTB compared to pulmonary tuberculosis (PTB). The purpose of this study was to characterise the clinical and treatment differences between EPTB and PTB patients, and identify patient factors associated with EPTB. STUDY DESIGN: We performed a retrospective cohort study of active tuberculosis (TB) cases treated at the Baltimore City Health Department between 2008 and 2013. METHODS: We categorised patients as having 'only PTB' (infection in the lung parenchyma), 'EPTB/PTB' (infection in the lung and an additional site), and 'only EPTB' (infection not involving the lung). Pearson's chi-squared tests were used to evaluate categorical variables and compare clinical and demographic differences between only PTB, only EPTB, and EPTB/PTB patients. Student t-tests and one-way analysis of variance tests were utilised to assess continuous variables and to compare treatment differences. RESULTS: One hundred and sixty-three patients were treated for TB; 39.3% had some form of EPTB (either EPTB/PTB or only EPTB). There was no difference found between EPTB, PTB, and EPTB/PTB patients with respect to HIV status, gender, race, foreign-born status, or mean age. Patients with only EPTB were less likely than patients with some form of PTB (only PTB or EPTB/PTB) to present with cough (30.4% vs 61.5%; P < 0.001), night sweats (10.9% vs 39.3%; P < 0.001), and weight loss (28.3% vs 47.9%; P = 0.023). Patients with some form of EPTB were also more likely to be hospitalised postdiagnosis compared to patients with only PTB (39.1% vs 20.2%; P = 0.009), and to have longer mean durations of treatment (37.9 weeks [SD = 11.1] vs 31.8 weeks [SD = 8.1]; P < 0.001). CONCLUSIONS: EPTB patients present with atypical symptoms, undergo prolonged treatment, and experience increased hospitalisations. In order to improve diagnostic algorithms and treatment modalities, EPTB must be further characterised.
OBJECTIVES: The proportion of extrapulmonary tuberculosis (EPTB) cases in the United States (US) has been rising due to a slower rate of decline in EPTB compared to pulmonary tuberculosis (PTB). The purpose of this study was to characterise the clinical and treatment differences between EPTB and PTBpatients, and identify patient factors associated with EPTB. STUDY DESIGN: We performed a retrospective cohort study of active tuberculosis (TB) cases treated at the Baltimore City Health Department between 2008 and 2013. METHODS: We categorised patients as having 'only PTB' (infection in the lung parenchyma), 'EPTB/PTB' (infection in the lung and an additional site), and 'only EPTB' (infection not involving the lung). Pearson's chi-squared tests were used to evaluate categorical variables and compare clinical and demographic differences between only PTB, only EPTB, and EPTB/PTBpatients. Student t-tests and one-way analysis of variance tests were utilised to assess continuous variables and to compare treatment differences. RESULTS: One hundred and sixty-three patients were treated for TB; 39.3% had some form of EPTB (either EPTB/PTB or only EPTB). There was no difference found between EPTB, PTB, and EPTB/PTBpatients with respect to HIV status, gender, race, foreign-born status, or mean age. Patients with only EPTB were less likely than patients with some form of PTB (only PTB or EPTB/PTB) to present with cough (30.4% vs 61.5%; P < 0.001), night sweats (10.9% vs 39.3%; P < 0.001), and weight loss (28.3% vs 47.9%; P = 0.023). Patients with some form of EPTB were also more likely to be hospitalised postdiagnosis compared to patients with only PTB (39.1% vs 20.2%; P = 0.009), and to have longer mean durations of treatment (37.9 weeks [SD = 11.1] vs 31.8 weeks [SD = 8.1]; P < 0.001). CONCLUSIONS: EPTB patients present with atypical symptoms, undergo prolonged treatment, and experience increased hospitalisations. In order to improve diagnostic algorithms and treatment modalities, EPTB must be further characterised.
Authors: Henry M Blumberg; William J Burman; Richard E Chaisson; Charles L Daley; Sue C Etkind; Lloyd N Friedman; Paula Fujiwara; Malgosia Grzemska; Philip C Hopewell; Michael D Iseman; Robert M Jasmer; Venkatarama Koppaka; Richard I Menzies; Richard J O'Brien; Randall R Reves; Lee B Reichman; Patricia M Simone; Jeffrey R Starke; Andrew A Vernon Journal: Am J Respir Crit Care Med Date: 2003-02-15 Impact factor: 21.405
Authors: Heather M Peto; Robert H Pratt; Theresa A Harrington; Philip A LoBue; Lori R Armstrong Journal: Clin Infect Dis Date: 2009-11-01 Impact factor: 9.079
Authors: Zhenhua Yang; Ying Kong; Frank Wilson; Betsy Foxman; Annadell H Fowler; Carl F Marrs; M Donald Cave; Joseph H Bates Journal: Clin Infect Dis Date: 2003-12-19 Impact factor: 9.079
Authors: Xu Qian; Duc T Nguyen; Jianxin Lyu; Andreas E Albers; Xiaohong Bi; Edward A Graviss Journal: Emerg Microbes Infect Date: 2018-06-06 Impact factor: 7.163
Authors: Sonya Krishnan; Artur T L Queiroz; Amita Gupta; Nikhil Gupte; Gregory P Bisson; Johnstone Kumwenda; Kogieleum Naidoo; Lerato Mohapi; Vidya Mave; Rosie Mngqibisa; Javier R Lama; Mina C Hosseinipour; Bruno B Andrade; Petros C Karakousis Journal: Front Immunol Date: 2021-06-08 Impact factor: 8.786